Translating Innovative Ideas Into

Translating Innovative Ideas Into

IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies we are developing. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets. We believe this diversified approach will enable us to deliver the right medicine to the right patient to drive a more robust clinical response. IDEAYA, headquartered in South San Francisco, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology, small molecule drug discovery, translational biology and clinical development.

Company OverviewRecent News

IDEAYA was founded with the premise that attracting the industry's best scientists and focusing on areas of transformative research is a proven model for delivering game-changing medicines to patients. Our people are passionate and proven cancer biologists, translational biologists, drug discovery chemists and development professionals. As an organization, we believe that our entrepreneurial spirit and nimbleness, and commitment to foster innovation, teamwork and excellence is what sets us apart. Our greatest asset is our scientists and their passion to discover innovative new therapies for cancer patients.

Yujiro S. HataIDEAYA Chief Executive Officer

Precision Medicine

We are pursuing an integrated approach for biomarker and small molecule drug discovery and development to broadly address unmet needs in cancer. Our capabilities include target and biomarker discovery integrated with small molecule therapeutics, from early discovery through clinical development. IDEAYA is employing a translational platform based on cutting-edge technologies for discovery, validation and clinical development of biomarkers in parallel with novel therapeutics.

Biomarker-enabled translational approaches help enhance patient outcomes – by identifying patients likely to respond to particular therapies and by providing clinical insights based on extent of target modulation.

Therapies Targeting Oncogenic Pathways

An understanding of tumor biology, in particular genomic alterations that drive cell proliferation and survival, enables an opportunity to develop therapies directly targeting an oncogenic pathway for cancers with limited or no effective treatments. IDEAYA is pursuing small molecule therapeutics with a goal of providing significant impact for patients with such genetically defined tumors.

Synthetic Lethality

Synthetic lethality occurs between two genes when the loss of function of either gene alone does not affect cell viability, but the simultaneous loss of function of both genes leads to cancer cell death. Mutated, amplified, and deleted genes in cancer have been catalogued, and a subset of historically undruggable targets can potentially be pursued indirectly, based on the concept of synthetic lethality.